Primmune Therapeutics
Andrew Rubinstein is a Co-Founder and Managing Partner at Oberland Capital. Previously, Mr. Rubinstein was a Partner at Paul Capital, where he co-managed the firm's healthcare royalty platform. Prior to joining Paul Capital, he was CEO of Microban International, Ltd. a global licensing business focused on antimicrobial technologies. Mr. Rubinstein had previously worked as an investment banker in the Financial Sponsors Group at Merrill Lynch & Co. He earned a B.A. from the University of Pennsylvania, a J.D. from New York University School of Law, and an M.B.A. from New York University Stern School of Business.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Primmune Therapeutics
1 followers
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.